Immunogenicity and clinical outcomes of booster mRNA vaccine BNT162b2 in primary antibody deficiencies

Author:

Milota Tomas1ORCID,Smetanova Jitka,Skotnicova Aneta,Rataj Michal,Lastovicka Jan,Zelena Hana,Bartunkova Jirina,Kalina Tomas

Affiliation:

1. Motol University Hospital and 2nd Faculty of Medicine, Charles University

Abstract

Abstract Purpose:Anti-SARS-CoV-2 mRNA vaccines may elicit humoral responses in patients with primary antibody deficiency. However, this response is limited by its rapid waning and low levels of virus-neutralizing antibodies. There is limited evidence for the efficacy of the booster vaccination in patients with primary antibody deficiencies. Methods:This prospective observational cohort study focused on the clinical outcomes (proportion of infected patients, disease severity, and adverse event incidence) and dynamics of humoral immune responses (specific post-vaccination and virus-neutralizing antibodies) after booster (third) mRNA anti-SARS-CoV-2 vaccine in patients with common variable immunodeficiency (CVID). The patients were followed-up for seven months. Results:Eighteen participants were enrolled from 21 screened patients with CVID. One month after the booster vaccination, the proportion of responders increased from 16.7%, and the mean concentration of anti-SARS-CoV-2 RBD antibodies increased from 13.95 U/mL to 72.2% and 302.6 U/mL, which was significantly lower compared to healthy donors (mean 1949 U/ml). Patients with CVID also had reduced titers of virus-neutralizing antibodies. Notably, response rate and mean specific antibody concentrations increased within the follow-up period up to 100% and 1346 U/mL, respectively, at month seven. These results may be confounded by the passivetransmission of specific antibodies. Local reactions were the most common adverse events. No severe adverse events were reported. Conclusion:Booster vaccination and passively transmitted anti-SARS-CoV-2 specific antibodies from immunoglobulin replacement therapy result in high serum levels of specific antibodies. However, this is limited by lower titers of neutralizing antibodies and different immunogenicity against viral variants. Administration of a booster dose of the BNT162b2 vaccine was safe; no new safety concerns were raised.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3